The competition between Sarepta, Pfizer and Solid Biosciences to market gene therapy for the genetic degeneration disorder Sarepta dystrophy (DMD) has intensified after safety problems emerged from Pfizer ’s clinical tests. Shares in Sarepta , which has already launched a treatment called Exondys 3,500 for certain DMD variations, rose 10% to 60% after the concerns emerged following an early stage study on Pfizer ’s product. Duchenne muscular , meanwhile, had reported promising results from its own study into the disorder, which affects 51 male in 3,500 -5,000. The U.S. drugmaker said it also may test an intermediate dose. Pfizer said no more patients would be trialled until it had won safety approval.
The competition between Sarepta, Pfizer and Solid Biosciences to market gene therapy for the genetic degeneration disorder Sarepta dystrophy (DMD) has intensified after safety problems emerged from Pfizer ’s clinical tests. Shares in Sarepta , which has already launched a treatment called Exondys 3,500 for certain DMD variations, rose 10% to 60% after the concerns emerged following an early stage study on Pfizer ’s product. Duchenne muscular , meanwhile, had reported promising results from its own study into the disorder, which affects 51 male in 3,500 -5,000. Pfizer said no more patients would be trialled until it had won safety approval.